- Zendal has received authorization from the European Medicines Agency (EMA) for a vaccine that enables immunization against three concurrent serotypes, simplifying vaccination strategies.
- In 2025, Zendal supplied more than 55 million doses of bluetongue and epizootic hemorrhagic disease (EHD) vaccines, both vector-borne viral diseases.
Porriño, Pontevedra (Spain), April 9, 2026.– The pharmaceutical group Zendal has obtained marketing authorization, through the centralized procedure(1), from the European Medicines Agency (EMA) for the first trivalent vaccine targeting serotypes 1, 4 and 8 of the bluetongue virus in sheep.
The new vaccine enables active immunization of sheep to prevent viremia caused by bluetongue virus serotypes 1, 4 and 8. It expands Zendal’s current portfolio of authorized monovalent and bivalent vaccines against bluetongue.
This development represents a significant milestone in animal health, providing an effective solution against three of the most epidemiologically relevant serotypes, which may circulate simultaneously and cause substantial health and economic impacts on livestock.
The trivalent approach is expected to have a positive impact on farms by optimizing animal health management and simplifying vaccination campaigns. This translates into clear benefits from a health, economic and logistical perspective for the livestock sector.
With this new European authorization, Zendal reinforces its commitment to animal health management and consolidates its position as a leading biotechnology company in Europe.
Effective control of diseases such as bluetongue not only protects livestock but also contributes to the sustainability of the agri-food system, reduces the economic impact on the sector and strengthens health security in a context of increasing epidemiological pressure and climate change.
Established leadership in the european market
Zendal has built a strong track record in the development of innovative bluetongue vaccines for more than 20 years and holds a solid position in the European market.
In 2025, international distribution of bluetongue vaccines (serotypes 1, 3, 4 and 8) reached 48 million doses, complemented by 8 million doses of vaccines against epizootic hemorrhagic disease (EHD).
The new trivalent vaccine, marketed as BLUEVAC BTV, expands Zendal’s portfolio of solutions for bluetongue and epizootic hemorrhagic disease, strengthening its ability to respond to different epidemiological scenarios.
In 2025, the group also received marketing authorizations from the European Medicines Agency for its vaccine against bluetongue virus serotype 3, for both bovine and ovine species, as well as for the first vaccine against epizootic hemorrhagic disease in cattle (commercial name HEPIZOVAC), both developed in response to emergency health situations.
These developments confirm Zendal’s leadership in Europe within this category of viral vaccines, reinforcing its position across most European markets and underlining its commitment to animal health and welfare in the region.
(1) Authorisation granted by the EMA to CZ Vaccines of the Zendal group.https://www.ema.europa.eu/en/medicines/veterinary/variation/bluevac-btv-previously-bluevac-btv8#:~:text=On%2012%20February%202026%2C%20the,QRD%20available%20(version%209.1).